The Latest
-
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
-
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.
-
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
-
Q&A
Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
-
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
Updated March 8, 2024 -
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.
-
Could pharma’s legal attack on the IRA succeed in killing price negotiations?
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
-
Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
-
Profile
HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
-
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead.
-
Biotech Spotlight
Black Diamond looks to outwit cancer mutations
Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.
-
Did the FTC get it wrong when it blocked the Sanofi-Maze deal?
In its zeal to stamp out anticompetitive practices and lower drug prices, a consultant said the FTC might have overlooked the unique considerations in rare disease drug development.
-
After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections
Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.
-
Q&A
Biogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
-
Can a top scientist and Moderna co-founder change the CRO game?
From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.
-
A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain
How research companies can shift strategies to attract and retain the staff that keeps trials humming along.
-
Profile
Behind a big-name rare disease biotech, an exec draws from personal experience
The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.
-
Ozempic for liver disease? Weight loss drugs could have even more to offer
GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.
-
How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues
Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.
-
Q&A
For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
-
AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma
Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.
-
BioMarin preaches patience amid slow sales for hemophilia gene therapy
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
-
Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health
Ferring’s U.S. president Brent Ragans discusses the company’s strategy as it expands into new therapeutic areas and further develops its reproductive pipeline.
-
Behind the breakthrough cancer therapy that just won a historic FDA nod
The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.
-
4 biotechs to watch in 2024
A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.